| Previous Close | 93.90 |
| Open | 92.63 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 93.90 - 93.90 |
| 52 Week Range | 77.45 - 97.30 |
| Volume | 50 |
| Avg. Volume | 22,456 |
| Market Cap | 210.814B |
| Beta (5Y Monthly) | 0.51 |
| PE Ratio (TTM) | 26.98 |
| EPS (TTM) | 3.48 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.22 (3.43%) |
| Ex-Dividend Date | Mar. 04, 2021 |
| 1y Target Est | N/A |
- Editor's PickYahoo Finance Video
FDA ‘shifting the bar’ for approval with new Alzheimer’s drug: Eli Lilly CEO
Eli Lilly CEO David Ricks joins 'Influencers with Andy Serwer' to discuss the FDA's approval of Biogen's new Alzheimer’s drug.
- Zacks
Pharma Stock Roundup: FDA Approval for NVO, PFE Products & Other Updates
FDA approves Novo Nordisk's (NVO) obesity treatment, Wegovy and Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine, Prevnar 20.
- GlobeNewswire
Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria
First-in-class, oral, targeted factor B inhibitor iptacopan substantially reduced both intra- and extravascular hemolysis when given as monotherapy in a Phase II study of anti-C5 naïve paroxysmal nocturnal hemoglobinuria (PNH) patients1New results are promising for potential use of iptacopan as monotherapy in PNH, a rare and life-threatening blood disorder2,3; results from a previous Phase II study showed iptacopan substantially improved hematological response as add-on to standard-of-care (ecul
